APA

Whitelaw B. C., Dworakowska D., Thomas N. W., Barazi S., Riordan-Eva P., King A. P., Hampton T., Landau D. B., Lipscomb D., Buchanan C. R., Gilbert J. A. & Aylwin S. J. B. (20120817). Temozolomide in the management of dopamine agonist-resistant prolactinomas. : Clinical endocrinology.

Chicago

Whitelaw B C, Dworakowska D, Thomas N W, Barazi S, Riordan-Eva P, King A P, Hampton T, Landau D B, Lipscomb D, Buchanan C R, Gilbert J A and Aylwin S J B. 20120817. Temozolomide in the management of dopamine agonist-resistant prolactinomas. : Clinical endocrinology.

Harvard

Whitelaw B. C., Dworakowska D., Thomas N. W., Barazi S., Riordan-Eva P., King A. P., Hampton T., Landau D. B., Lipscomb D., Buchanan C. R., Gilbert J. A. and Aylwin S. J. B. (20120817). Temozolomide in the management of dopamine agonist-resistant prolactinomas. : Clinical endocrinology.

MLA

Whitelaw B C, Dworakowska D, Thomas N W, Barazi S, Riordan-Eva P, King A P, Hampton T, Landau D B, Lipscomb D, Buchanan C R, Gilbert J A and Aylwin S J B. Temozolomide in the management of dopamine agonist-resistant prolactinomas. : Clinical endocrinology. 20120817.